Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 81

  • 26

  • 16

  • 12

  • 11

  • 8

  • 7

  • 6

  • 6

  • 5

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

Efficacy of immunotherapy in the first and second line treatment of metastatic bladder cancer

Funder: German Research Foundation

Funding period
0
Funding amount
Abstract
Since the implementation of checkpoint inhibitors in the sequence therapy of metastatic bladder cancer just a few years ago, a new era for one of the most common tumor entities in Europe has begun. However, only a few studies on checkpoint therapy are available today. Most of these studies are phase-II, to some extent with small patient populations. This situation may cause a distortion in the estimated effects of immunotherapy or worst a distortion of the study results. Aim of this research project is the preparation of a Cochrane Review on immunotherapy for metastatic bladder cancer, which summarizes the current state of knowledge of this new therapy. Cochrane Reviews are internationally recognized as a quality standard in evidence-based medicine. According to the Cochrane guidelines, a systematic literature review, a systematic data extraction as well as data evaluation in terms of a meta-analysis will be carried out at the highest level of methodological quality. The scientific benefit of this Cochrane Review is a summary and evaluation of the currently available evidence. Compared to many individual studies, this evidence synthesis and -assessment helps to improve the trustworthiness of the estimated effects for the benefits or harms of an immunotherapy for metastatic bladder cancer. As a clinical benefit, these results will help to better quantify the effects and impairments of immunotherapy on affected patients. Due to the implementation of this Cochrane Review into clinical routine (e.g. guidelines), patient’s treatment should be improved.

 
220
Projects
USD 114.9 M
Aggregated funding amount
USD 676 K
Average funding amount
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Ciriaco A. Piccirillo, Jonathan David Spicer

USD 138,878
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020
Project list item
Chemotherapy plus PD-1 blockade as bladder-sparing treatment for muscle-invasive bladder cancer

V Foundation for Cancer Research to Matthew D Galsky

USD 600,000
2019 - 2022
Project list item
Unravelling Mechanisms of Resistance to Checkpoint Inhibition in Canine Urothelial Carcinoma

V Foundation for Cancer Research to Nicola J. Mason

USD 500,000
2019 - 2021
Project list item
[The association between SORL1 and advanced bladder cancer] - Original in Japanese

Japan Society for the Promotion of Science to Takanobu UTSUMI

USD 26,335
2019 - 2021
Project list item
Targeting FGF in Bladder cancer after Neoadjuvant Immunotherapy and Surgery

American Association For Cancer Research to Joshua James Meeks

USD 25,000
2019 - 2020
Project list item
Identifying Immunological Basis for Bladder Cancer Sex Bias

Canadian Institutes of Health Research to Hyunwoo Kwon, Zihai Li

USD 45,605
2019 - 2022
Project list item
[Studies on a novel immunotherapy for bladder cancer by NAD+] - Original in Japanese

Japan Society for the Promotion of Science to 博史 上原, Kazumasa Komua, Haruhito AZUMA

USD 39,508
2019 - 2024
Project list item
[Chemoradiotherapy with MMC and UFT for muscle-invasive bladder cancer in elderly patients] - Original in Japanese

Japan Society for the Promotion of Science to Hisanori ARIGA, 光洋 菊池

USD 35,916
2019 - 2024
Project list item
[Cancer immunotherapy targeting treatment-resistant urothelilal cancer stem cells] - Original in Japanese

Japan Society for the Promotion of Science to 愛子 村井

USD 38,275
2019 - 2021
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 372,404
2019 - 2021
Project list item
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer

National Cancer Institute to BYRON H LEE

USD 486,410
2019 - 2024
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 1,313,632
2019 - 2024
load more...